MedTrace Logo

Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment

NCT03326505 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-04

No results posted yet for this study

Summary

This study aims at expanding Umbilical Cord derived Mesenchymal Stem Cells (MSCs) to a clinical scale according to Good Laboratory Practice and study its efficacy when compared to a Supervised Physical Therapy Program alone.

Conditions

Interventions

BIOLOGICAL

Umbilical cord derived Mesenchymal Stem Cells

Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients

OTHER

Supervised physical therapy

A combined physical therapy program of Balance, strengthening and endurance exercises

Sponsors & Collaborators

  • University of Jordan

    lead OTHER

Principal Investigators

  • Abdallah Awidi, MD · Cell Therapy Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2020-01-25
Completion
2020-02-20

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326505 on ClinicalTrials.gov